HMGN partial peptide and cancer therapy using the same
US11572393B2 · kind B2 · utility
1Cited by
3References
21Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Mar 7, 2019 |
| Grant date | Feb 7, 2023 |
| Priority date | — |
| Expiry date | Mar 7, 2039 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2039/545
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed are a novel therapeutic means effective and practical against cancer, and a novel substance useful as such a therapeutic means. Provided are novel peptides derived from a partial region of HMGN1, HMGN2, HMGN4 or HMGN5, and anti-cancer agents and anti-cancer effect enhancers containing the peptide as an active ingredient. The peptide of the present invention has an anti-tumor effect even independently, and exerts a remarkably excellent anti-tumor effect particularly when used in combination with an immune checkpoint regulator, or an anti-CD4 antibody or antigen-binding fragment thereof.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.